shisa family member 2Genealiases: C13orf13 · PRO28631 · TMEM46 · WGAR9166 · bA398O19.2 · hShisa
Q-omics provides the consensus-scored SHISA2 profile across patient tissues and cancer cell-line models. SHISA2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SHISA2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SHISA2 RNA expression shows 16,323 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where SHISA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHISA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHISA2 survival associations across molecular data types. SHISA2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHISA2 RNA expression–survival associations across cancer types. High SHISA2 expression shows unfavorable associations in UVM, ACC, MESO and TGCT, but favorable associations in LUAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SHISA2 RNA expression.
This table summarizes SHISA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SHISA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHISA2 shows lower tumor expression in KIRC, LUAD and THCA and higher tumor expression in HNSC, COAD and BLCA. The KIRC box plot shows higher SHISA2 RNA expression in normal versus tumor tissue (log2 FC = −2.537, t-test p < 0.001).
This table shows molecular features associated with SHISA2 in patient tissues and cancer cell lines. In patient samples, SHISA2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SHISA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
